Open AccessS695 Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
Author(s) -
Stefan Schreiber,
Marc Ferrante,
Remo Panaccione,
Jean–Frédéric Colombel,
Tadakazu Hisamatsu,
Allen Lim,
James O. Lindsay,
David T. Rubin,
William J. Sandborn,
Ezequiel Neimark,
Alexandra Song,
Xiaomei Liao,
Feng Tian,
Sofie Berg,
Kori Wallace,
G D’Haens
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776312.86615.e5
Subject(s) - medicine , crohn's disease , placebo , population , gastroenterology , clinical trial , randomized controlled trial , disease , pathology , alternative medicine , environmental health